Seres Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Seres Therapeutics, Inc. (MCRB) reported Increase (Decrease) in Contract with Customer, Liability of -$4.36 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2022-03-01
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-06-30 was -$5.26M.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-03-31 was -$4.65M.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-12-31 was $352.00K, a 86.24% increase year-over-year.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-09-30 was -$80.00K.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$4.36M.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$11.56M.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2019 was -$17.52M, a 230.01% decline from fiscal 2018.
- Seres Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2018 was $13.48M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$4.36M 10-K · filed 2022-03-01 | |||
| 2021-06-30 | -$5.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$9.91M 10-Q · filed 2021-08-03 | -$9.56M derived: sum of 3 quarters · filed 2022-03-01 | -$9.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | -$4.65M 10-Q · filed 2021-05-04 | -$4.30M derived: sum of 2 quarters · filed 2022-03-01 | -$4.38M derived: sum of 3 quarters · filed 2022-03-01 | -$9.58M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $272.00K derived: sum of 2 quarters · filed 2022-03-01 | -$4.93M derived: sum of 3 quarters · filed 2022-03-01 | -$11.56M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$5.28M derived: sum of 2 quarters · filed 2021-08-03 | -$11.92M 10-Q · filed 2020-11-09 | -$11.73M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$11.84M 10-Q · filed 2021-08-03 | -$11.65M derived: sum of 3 quarters · filed 2022-03-01 | -$17.73M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$6.63M 10-Q · filed 2021-05-04 | -$6.45M derived: sum of 2 quarters · filed 2022-03-01 | -$12.53M derived: sum of 3 quarters · filed 2022-03-01 | -$23.95M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$5.89M derived: sum of 2 quarters · filed 2022-03-01 | -$17.31M derived: sum of 3 quarters · filed 2022-03-01 | -$17.52M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$6.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$17.50M derived: sum of 2 quarters · filed 2020-11-09 | -$17.71M 10-Q · filed 2020-11-09 | $12.10M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | -$11.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | -$11.63M 10-Q · filed 2020-07-28 | $18.18M derived: sum of 3 quarters · filed 2021-03-02 | $9.71M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | -$208.00K 10-Q · filed 2020-05-07 | $29.60M derived: sum of 2 quarters · filed 2021-03-02 | $21.13M derived: sum of 3 quarters · filed 2021-03-02 | $16.86M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $29.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $21.34M derived: sum of 2 quarters · filed 2021-03-02 | $17.07M derived: sum of 3 quarters · filed 2021-03-02 | $13.48M 10-K · filed 2021-03-02 |
| 2018-09-30 | -$8.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$12.74M derived: sum of 2 quarters · filed 2019-11-05 | -$16.33M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$4.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$7.86M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$3.59M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | -$11.89M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $108.81M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |